Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre
African Health Sciences · 2023
DOI: 10.4314/ahs.v23i1.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2023. Verfasst von Abdulmuminu Isah und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Nigeria Nsukka, Department of Clinical Pharmacy and Pharmacy Management. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Dolutegravir (DTG) based antiretroviral therapy (ART) has largely replaced Efavirenz (EFV) based therapy as the preferred first-line regimen in the treatment of adults with HIV. This study was carried out to evaluate the comparative cost-effectiveness of DTG and EFV-based ART in HIV-infected treatment-naïve patients in a treatment centre in Nigeria.
Methods
This was a retrospective case-control study of patients initiated on DTG vs. EFV-based regimens from January 2018 to December 2019 at the APIN/HAVARD clinic of Nigeria’s Jos University Teaching Hospital. The current viral load result was used to determine treatment effectiveness using a benchmark of ≤200 copies/mL. Sensitivity analysis was carried out to ensure the robustness of the benchmark. The total cost of treatment was obtained by summing up the relevant cost components. Appropriate descriptive and inferential statistics were employed in data analysis using Statistical Product and Services Solutions (SPSS) V.25. The incremental cost-effectiveness ratio of DTG compared to EFV was presented as cost/effectiveness.
Results
Treatment was effective in 42(51.9%) and 58(71.6%) patients initiated on DTG and EFV-based regimen, respectively. The incremental cost-effective ratio (ICER) of patients on DTG compared to those on EFV was $10.5076 per effectiveness, which was less than 1% of the Nigerian 2019 per capita Gross Domestic Product. Sensitivity analysis showed the robustness of the result.
Conclusion
Efavirenz based regimen had higher treatment effectiveness than DTG-based regimen in treatment-naive patients after initiating treatment in a short term. Compared to EFV, DTG-based regimen is cost-effective in the management of treatment naïve HIV patients. Keywords: Average cost-effectiveness ratio; cost-effectiveness; Dolutegravir.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Nigeria Nsukka, Department of Clinical Pharmacy and Pharmacy Management.
- University of Nigeria Teaching Hospital, Department of Pharmaceutical Services.
- National Assembly, Department of Pharmacy.
- Nnamdi Azikiwe University, Department of Pharmacy and Pharmacy Management.
Zitieren
APA
Isah, A., Chukwu, P. O., Abba, A., Igboeli, N. U., Ebere, A., Omotola, O. F., Alozie, F. A., Ekwunife, O. I., & Adibe, M. O. (2023). Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre. African Health Sciences. https://doi.org/10.4314/ahs.v23i1.18
Vancouver
Isah A, Chukwu PO, Abba A, Igboeli NU, Ebere A, Omotola OF, et al. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre. African Health Sciences. 2023. doi:10.4314/ahs.v23i1.18
BibTeX
@article{Isah2023,
author = {Isah, Abdulmuminu and Chukwu, Patrick O and Abba, Abubakar and Igboeli, Nneka U and Ebere, Ayogu and Omotola, Olusegun F and Alozie, Faith A and Ekwunife, Obinna I and Adibe, Maxwell O},
title = {Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre},
journal = {African Health Sciences},
year = {2023},
doi = {10.4314/ahs.v23i1.18}
}
EUVIMED